Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | GSK3B | P49841 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 4/20 | 0.57 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.57 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYBB | P04839 | 2/20 | 0.47 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4106460 | 1.00 | MEN1 (0.60) | MEN1KMT2ALMNAMAPTGSK3B | |
| SCHEMBL13846846 | 1.00 | MEN1 (0.60) | MEN1KMT2ALMNAMAPTGSK3B | |
| SCHEMBL15421798 | 0.81 | POLB (0.79) | MEN1KMT2AMAPTGSK3BALDH1A1 | |
| SCHEMBL15421800 | 0.81 | POLB (0.79) | MEN1KMT2AMAPTGSK3BALDH1A1 | |
| SCHEMBL15421799 | 0.81 | POLB (0.79) | MEN1KMT2AMAPTGSK3BALDH1A1 | |
| SCHEMBL9632830 | 0.76 | ALDH1A1 (0.60) | MEN1KMT2ALMNAMAPTALDH1A1 | |
| SCHEMBL9692136 | 0.76 | MAPT (0.57) | MEN1KMT2ALMNAMAPTGSK3B | |
| SCHEMBL9692140 | 0.76 | MAPT (0.57) | MEN1KMT2ALMNAMAPTGSK3B | |
| SCHEMBL8218253 | 0.76 | GSK3B (1.00) | MEN1KMT2ALMNAMAPTGSK3B | |
| SCHEMBL16685430 | 0.76 | GSK3B (1.00) | MEN1KMT2ALMNAMAPTGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-1585541-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-11-14 | — | — | EP | disclosed |
| US-20060258561-A1 | Novel NPH insulin preparations | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | US | disclosed |
| WO-2006082245-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING INSULIN, ZINC IONS AND A ZINC-BINDING LIGAND | NOVO NORDISK A/S (DK) | 2006-08-10 | — | — | WO | disclosed |
| US-20060069013-A1 | Pharmaceutical preparations comprising acid-stabilised insulin | NOVO NORDISK A/S (DK) | 2006-03-30 | — | — | US | disclosed |
| EP-1610812-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2006-01-04 | — | — | EP | disclosed |
| EP-1605967-A1 | NOVEL NPH INSULIN PREPARATIONS | NOVO NORDISK A/S (DK) | 2005-12-21 | — | — | EP | disclosed |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | NOVO NORDISK A/S (DK) | 2005-03-24 | — | — | US | disclosed |
| WO-2004080481-A1 | NOVEL NPH INSULIN PREPARATIONS | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004080480-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258561-A1 | Novel NPH insulin preparations | IAPP, HBB, INSR | MEN1 680/4885KMT2A 4399/4885LMNA 4147/4885 |
| US-20060069013-A1 | Pharmaceutical preparations comprising acid-stabilised insulin | IAPP, GPR119, INSR | MEN1 395/4885KMT2A 4638/4885LMNA 4418/4885 |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | IAPP, IRS1, INSR | MEN1 299/4885KMT2A 4420/4885LMNA 4335/4885 |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | MEN1 912/4885KMT2A 4327/4885LMNA 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.